TD Securities (USA)’s Vertex Pharmaceuticals VRTX Stock Holding History

TD Securities (USA)’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$4K	Buy	56 +1	+2%	+$90	0.04%	256
2015 Q4	$7K	Sell	55 -85	-61%	-$10.3K	0.06%	144
2015 Q3	$15K	Sell	140 -98,578	-100%	-$12.7M	0.14%	161
2015 Q2	$12.2M	Buy	98,718 +11,750	+14%	+$1.48M	0.17%	149
2015 Q1	$10.3M	Sell	86,968 -4,366	-5%	-$523K	0.15%	163
2014 Q4	$10.8M	Buy	91,334 +8,055	+10%	+$907K	0.16%	157
2014 Q3	$9.35M	Buy	83,279 +710	+0.9%	+$67.6K	0.15%	163
2014 Q2	$7.82M	Buy	82,569 +5,198	+7%	+$364K	0.13%	196
2014 Q1	$5.47M	Sell	77,371 -5,101	-6%	-$404K	0.1%	251
2013 Q4	$6.13M	Buy	82,472 +2,760	+3%	+$192K	0.1%	227
2013 Q3	$6.04M	Buy	+79,712	New	+$6.34M	0.12%	212

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TD Securities (USA)'s VRTX Position: Q1 2016 in Review

TD Securities (USA) increased its Vertex Pharmaceuticals (VRTX) stake by 1.8% in Q1 2016, buying an estimated $90 and bringing the position to 56 shares worth $4K. The position accounts for 0.04% of the portfolio, ranked #256.

TD Securities (USA) first reported a position in VRTX in Q3 2013 and has held it in 11 quarters since. The position peaked at $12.2M in Q2 2015. 503 funds tracked by Wall St. Rank hold VRTX as of Q1 2016.

TD Securities (USA) held 56 shares of Vertex Pharmaceuticals worth $4K as of Q1 2016.
TD Securities (USA) bought 1 Vertex Pharmaceuticals share in Q1 2016, an estimated $90.
Vertex Pharmaceuticals made up 0.04% of TD Securities (USA)'s portfolio in Q1 2016, its #256 holding.
TD Securities (USA) first reported a position in Vertex Pharmaceuticals in Q3 2013 and has held it in 11 quarters since.
TD Securities (USA)'s Vertex Pharmaceuticals position peaked at $12.2M in Q2 2015.
503 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2016.

Based on TD Securities (USA)'s 13F filing for Q1 2016, filed 27 Apr 2016.